Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapy stocks.

Immunotherapy Stocks Recent News

Date Stock Title
Nov 22 REPL S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Nov 22 REPL Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
Nov 22 REPL Replimune climbs after updates on lead drug
Nov 22 REPL Replimune's stock surges 19% after-hours on FDA BLA submission
Nov 21 REPL Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
Nov 21 CDTX Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
Nov 21 IBRX ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Nov 21 CDTX Cidara Therapeutics shares surge on $105M equity private placement
Nov 21 CDTX Cidara Therapeutics Announces $105 Million Private Placement
Nov 20 IBRX High Growth Tech Stocks To Watch In November 2024
Nov 20 GDTC Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Nov 19 TVGN Tevogen Bio Holdings reports Q3 results
Nov 19 TVGN Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Nov 19 CDTX Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
Nov 19 IBRX ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags